# Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults

> **NCT05976386** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 182 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Dupilumab (SAR231893)

## Key facts

- **NCT ID:** NCT05976386
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-08
- **Primary completion:** 2021-09-24
- **Final completion:** 2021-09-24
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05976386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05976386, "Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05976386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*